COVID-19: seroprevalence and adherence to preventive measures in Arkhangelsk, Northwest Russia

Infect Dis (Lond). 2023 May;55(5):316-327. doi: 10.1080/23744235.2023.2179660. Epub 2023 Mar 15.

Abstract

Background: The published estimates of SARS-CoV-2 seroprevalence in Russia are few. The study aimed to assess the SARS-CoV-2 seroprevalence in Arkhangelsk (Northwest Russia), in a year after the start of the pandemic, to evaluate the population adherence to non-pharmaceutical interventions (NPIs), and to investigate characteristics associated with COVID-19 seropositive status.

Methods: We conducted a SARS-CoV-2 seroprevalence study between 24 February and 30 June 2021 involving 1332 adults aged 40-74 years. Logistic regression models were fit to identify factors associated with seropositive status and with adherence to NPIs.

Results: Less than half (48.9%) of study participants adhered all recommended NPIs. Male sex (odds ratio [OR] 1.7, 95% confidence intervals [CI] 1.3; 2.3), regular employment (OR 1.8, 95% CI 1.3; 2.5) and low confidence in the efficiency of the NPIs (OR 1.9, 95% CI 1.5; 2.5) were associated with low adherence to internationally recommended NPIs. The SARS-CoV-2 seroprevalence rate was 65.1% (95% CI: 62.5; 67.6) and increased to 73.0% (95% CI: 67.1; 85.7) after adjustment for test performance. Regular employment (OR 2.0, 95% CI 1.5; 2.8) and current smoking (OR 0.4, 95% CI 0.2; 0.5) were associated with being seropositive due to the infection.

Conclusions: Two third of the study population were seropositive in a year after the onset of the pandemic in Arkhangelsk. Individuals with infection-acquired immunity were more likely to have regular work and less likely to be smokers. The adherence to NPIs was not found associated with getting the virus during the first year of the pandemic.

Keywords: COVID-19; Russia; SARS-CoV-2; non-pharmaceutical interventions; seroprevalence.

MeSH terms

  • Adult
  • Antibodies, Viral
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Employment
  • Humans
  • Male
  • Russia / epidemiology
  • SARS-CoV-2
  • Seroepidemiologic Studies

Substances

  • Antibodies, Viral